AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 142 min read$PBH

Prestige Consumer Healthcare Inc. (PBH): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pbh-20260810 0001295947 false 0001295947 2026-08-10 2026-08-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________ FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of ea

Original reporting
SEC EDGAR 8-K
Published Aug 14, 2026, 8:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$PBH
Neutral
medium confidence
Mentioned
$PBH
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PBHNeutralLow
01

Why it matters

This is a governance and leadership continuity disclosure. Without disclosed replacement terms or operational changes, it is more relevant for monitoring succession than for repricing near-term earnings power.

02

Market read

Traders may watch for follow-on disclosures naming a successor or detailing compensatory arrangements, but the provided text alone does not change fundamentals.

03

What to watch

The filing references compensatory arrangements and director/officer appointments, but the provided text does not include specifics, so the true market impact may depend on details omitted from the scrape.

Relevance 6/10Novelty 3/10Timing: effective Aug. 14, 2026 for the operations SVP retirement, filed Aug. 14, 2026

Background

The company filed an SEC Form 8-K (Item 5.02) covering departure of a senior officer and related board/officer actions and compensatory arrangements.

Company-level read

Ticker impact

$PBHNeutralMedium confidence
Context

Prestige Consumer Healthcare disclosed in an 8-K that SVP Operations Jeffrey Zerillo will retire effective Aug. 14, 2026.

Expected impact

Likely limited immediate impact; any move would be sentiment-driven around succession rather than fundamentals.

Evidence & confidence

The filing confirms a retirement and effective date, but does not include replacement details, restructuring, or financial targets that would directly reset valuation.

Market effects

Sector

Minimal sector read-through; this is company-specific leadership turnover without disclosed operational or regulatory changes.

Regional

No clear regional spillover indicated by the filing.

Global

No global catalyst described beyond internal management changes.

Counterpoint

What could challenge this read

The retirement could be routine succession planning and may not signal operational risk; traders may overreact to the headline without replacement or restructuring details.

Key entities

  • issuer
    Prestige Consumer Healthcare Inc.

    Subject of the 8-K; disclosed retirement of SVP Operations Jeffrey Zerillo effective Aug. 14, 2026.

  • executive
    Jeffrey Zerillo

    Senior Vice President, Operations, who notified the company of his retirement effective Aug. 14, 2026.

  • executive
    Christine Sacco

    CFO and COO who signed the filing on Aug. 14, 2026.

Read at source← All news

Related articles

AUG 13
$PBHMed

Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?

Prestige Consumer Healthcare (NYSE:PBH) reported Q1 fiscal 2027 sales of $265.7M (+6.5% YoY) and adjusted diluted EPS of $0.98. The company closed Breathe Right (June 12) and LaCorium Health (July 1), adding about $240M annualized revenue and raising FY sales guidance to $1.29B-$1.315B and adjusted EPS to $4.55-$4.65. Clear Eyes faces supply constraints; acquisitions were funded with new debt.

insidermonkey.com6 min
AUG 13
$PBHMed

Prestige Consumer Healthcare (PBH) Q1 2027 Earnings Call Transcript

Prestige Consumer Healthcare (PBH) reported Q1 fiscal 2027 sales of about $266 million, up 6.5%, with growth led by GI brands such as Dramamine and Fleet and skin care brands including Compound W. Adjusted EPS rose to $0.98 and adjusted free cash flow reached $83.7 million. PBH also completed acquisitions of the Breathe Right portfolio (closed June 12) and LaCorium (July 1).

yahoo.com10 min
AUG 6
$PBHMedAI 8/10

PREMIUM BRANDS HOLDINGS CORPORATION REPORTS RECORD SECOND QUARTER SALES, ADJUSTED EBITDA AND ADJUSTED EARNINGS AND DECLARES THIRD QUARTER DIVIDEND

Premium Brands Holdings (TSX: PBH) reported record Q2 2026 results. Revenue rose to $2.4B, up 26.3% year over year, with 7.5% organic sales growth. Adjusted EBITDA from continuing operations increased to $225.0M and adjusted EPS to $1.53. The company declared a $0.85 dividend for Q3 and revised 2026 guidance due to delayed promotions/new product launches.

leaderpost.com6 min
AUG 6
$PBHHigh

Prestige Consumer Healthcare Inc. (PBH): Results of Operations and Financial Condition

Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991fy27-q1earningsr.htm EX-99.1 Document Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results • Q1 Revenue of $265.7 million up 6.5% versus prior year • Q1 Organic sales growth of 3.2%, exceeding expectations • Q1 Diluted EPS o

SEC EDGAR 8-K6 min
JUN 16
$PBHMed

Prestige Consumer Healthcare Inc. (PBH): Completion of Acquisition or Disposition of Assets

Prestige Consumer Healthcare Inc. (PBH) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001295947 0001295947 2026-06-12 2026-06-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of repor

SEC EDGAR 8-K4 min